A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Condition(s):Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-CellLast Updated:November 28, 2016Completed
Hide Studies Not Open or Pending
Condition(s):Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-CellLast Updated:November 28, 2016Completed
Condition(s):LymphomaLast Updated:January 23, 2017Terminated
Condition(s):DLBCL; MCL; Recurrent DiseaseLast Updated:March 19, 2018Terminated
Condition(s):Diffuse Large B-cell LymphomaLast Updated:February 1, 2024Recruiting
Condition(s):Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, FollicularLast Updated:November 18, 2023Recruiting
Condition(s):Diffuse Large B Cell LymphomaLast Updated:January 9, 2023Not yet recruiting
Condition(s):Diffuse Large B-cell LymphomaLast Updated:March 5, 2024Active, not recruiting
Condition(s):LymphomaLast Updated:July 18, 2018Unknown status
Condition(s):DLBCLLast Updated:August 19, 2022Not yet recruiting
Condition(s):Diffuse Large B-cell LymphomaLast Updated:April 18, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.